The Fort Worth Press - Quantum Biopharma Ltd. Approved to Dual List on Upstream

USD -
AED 3.672502
AFN 63.999675
ALL 82.464942
AMD 358.505756
ANG 1.790403
AOA 917.510995
ARS 1549.890095
AUD 1.484825
AWG 1.8025
AZN 1.69797
BAM 1.779156
BBD 2.017129
BDT 124.690139
BGN 1.77347
BHD 0.378157
BIF 3007.43672
BMD 1
BND 1.291033
BOB 11.682086
BRL 5.779027
BSD 1.001496
BTN 94.002656
BWP 14.018585
BYN 3.009424
BYR 19600
BZD 2.014218
CAD 1.429435
CDF 2317.999891
CHF 0.83897
CLF 0.025357
CLP 997.979888
CNY 6.66455
CNH 6.665825
COP 3317.23
CRC 446.292118
CUC 1
CUP 24.035623
CVE 100.306108
CZK 22.186203
DJF 178.348063
DKK 6.795935
DOP 60.867113
DZD 137.037458
EGP 53.662197
ERN 15
ETB 164.376481
EUR 0.90915
FJD 2.296803
FKP 0.758367
GBP 0.758115
GEL 2.594964
GGP 0.758367
GHS 11.732118
GIP 0.758367
GMD 73.502857
GNF 8873.120921
GTQ 7.654066
GYD 209.544342
HKD 7.846115
HNL 26.932961
HRK 6.831965
HTG 131.250142
HUF 331.546502
IDR 18244.45
ILS 3.24895
IMP 0.758367
INR 93.405104
IQD 1518.259596
IRR 1925253.999473
ISK 124.35966
JEP 0.758367
JMD 158.794125
JOD 0.708992
JPY 159.022498
KES 130.110117
KGS 87.449399
KHR 4106.5296
KMF 447.499173
KPW 900.00035
KRW 1336.755015
KWD 0.31145
KYD 0.834633
KZT 445.59873
LAK 22549.202436
LBP 89683.974965
LKR 333.298462
LRD 170.2507
LSL 16.970744
LTL 2.95274
LVL 0.60489
LYD 6.470746
MAD 9.982716
MDL 18.317444
MGA 4555.8128
MKD 55.929347
MMK 2099.8229
MNT 3605.49036
MOP 8.0932
MRU 40.667528
MUR 47.859706
MVR 15.410094
MWK 1736.583325
MXN 18.495385
MYR 4.092502
MZN 63.910547
NAD 16.970667
NGN 1345.960111
NIO 36.851561
NOK 9.65092
NPR 150.403886
NZD 1.81806
OMR 0.384507
PAB 1.001465
PEN 3.415402
PGK 4.572229
PHP 63.696003
PKR 276.920096
PLN 4.00304
PYG 6215.118421
QAR 3.660925
RON 4.861402
RSD 106.933007
RUB 82.456407
RWF 1479.507134
SAR 3.763042
SBD 8.098361
SCR 13.836741
SDG 601.49917
SEK 10.091803
SGD 1.288155
SHP 0.758581
SLE 23.050189
SLL 20969.503664
SOS 572.372042
SRD 37.453497
STD 20697.981008
STN 22.288025
SVC 8.762969
SYP 13002.000337
SZL 16.966036
THB 33.795502
TJS 9.228432
TMT 3.51
TND 3.027513
TOP 2.40776
TRY 50.417725
TTD 6.801694
TWD 32.904501
TZS 2648.102992
UAH 45.525197
UGX 4156.319079
UYU 40.6615
UZS 12027.818082
VES 914.603598
VND 25741
VUV 120.845902
WST 2.802705
XAF 596.363137
XAG 0.021086
XAU 0.000258519845
XCD 2.70255
XCG 1.8049
XDR 0.707052
XOF 596.363137
XPF 108.488699
YER 236.510374
ZAR 16.92753
ZMK 9001.19816
ZMW 20.506056
ZWL 321.999592
SSP 5946.953244
MXV 2.074894
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Quantum Biopharma Ltd. Approved to Dual List on Upstream
Quantum Biopharma Ltd. Approved to Dual List on Upstream

Quantum Biopharma Ltd. Approved to Dual List on Upstream

Trading to become available January 14th under 'QNTM'

Text size:

Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), today announced its approval to dual list its shares on Upstream, a MERJ Exchange market and global securities trading app. Trading becomes available on Upstream Tuesday, January 14, 2025, at 10:00am ET under the ticker symbol 'QNTM.'

The dual listing on Upstream is designed to provide Quantum the opportunity to access a global investor base outside of the U.S. that can trade using a credit/debit card, PayPal, USD, or USDC; unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in the company.

Investors outside of the U.S. can get ready to trade by downloading Upstream from their preferred app store at https://upstream.exchange/, creating an account by tapping Sign Up, and completing a simple KYC identity verification by tapping the profile icon on the home screen and tapping KYC.

Existing non-U.S. shareholders may initiate the transfer of their shares by opening Upstream, tapping Investor, Manage Securities, Deposit Securities, then entering the ticker symbol 'QNTM' and the number of shares to deposit, and tapping Submit. Next, investors enter their brokerage firm name and brokerage account number, then tap Submit. Lastly, investors tap Add E-Signature, sign their name on the screen using their finger, tap Done, and then tap Sign.

After completion of the deposit request on Upstream, shareholders will receive via email an executed deposit form to submit to their current brokerage firm to initiate a withdrawal to the transfer agent. Shares will not be transferred without notifying the current broker and requesting a withdrawal. On listing day, shareholders will receive a push notification once the shares are deposited and available for trading on Upstream.

Details on the Quantum listing, deposit, and trading instructions can be found at https://www.quantumbiopharma.com/investors. The Upstream market is open 7 days a week 20 hours a day, Monday to Sunday: 10:00am to 06:00am UTC+4 (1:00am to 9:00pm EST).

Traders on Upstream's smart contract-powered platform will experience real-time trading and settlement, and a transparent orderbook which does not permit common market manipulations.

Zeeshan Saeed, CEO of Quantum commented, "Building shareholder value is an ongoing goal of ours. We believe a dual listing on Upstream's next generation market supports this goal as we continue to develop our potential game changing drug candidates for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders that impact people from all over the world."

About Quantum BioPharma Ltd.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Celly Nutrition Corp. ("Celly Nutrition"), led by industry veterans. Quantum BioPharma retains ownership of 25.71% (as of June 30, 2024) of Celly Nutrition at www.unbuzzd.com. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd ™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

About Upstream

Upstream, a MERJ Exchange market (https://merj.exchange/), is a global securities trading app. Powered by Horizon's proprietary, transparency-first, matching engine, Upstream allows investors outside of the U.S. to trade securities using just an app. For more information, please visit https://upstream.exchange/. Upstream is currently accepting applications to dual list at https://upstream.exchange/getlisted.

Disclaimers

U.S. persons may not deposit, buy, or sell securities on Upstream.

This communication shall not constitute an offer to sell securities or the solicitation of an offer to buy securities in any jurisdiction where such offer or solicitation is not permitted. All orders for sale are non-solicited by Upstream and a user's decision to trade securities must be based on their own investment judgment.

Upstream is a MERJ Exchange market. MERJ Exchange is a licensed Securities Exchange, an affiliate of the World Federation of Exchanges, a National Numbering Agency, and a member of ANNA. MERJ is regulated in the Seychelles by the Financial Services Authority, https://fsaseychelles.sc/, an associate member of the International Association of Securities Commissions (IOSCO). MERJ supports global issuers of traditional and digital securities through the entire asset life cycle from issuance to trading, clearing, settlement, and registry. It operates a fair and transparent marketplace in line with international best practices and principles of operations of financial markets. Upstream does not endorse or recommend any public or private securities bought or sold on its app. Upstream does not offer investment advice or recommendations of any kind. All services offered by Upstream are intended for self-directed clients who make their own investment decisions without aid or assistance from Upstream. All customers are subject to the rules and regulations of their jurisdiction. By accessing the site or app, you agree to be bound by its terms of use and privacy policy. Company and security listings on Upstream are only suitable for investors who are familiar with and willing to accept the high risk associated with speculative investments, often in early and development-stage companies. U.S. persons may not deposit, buy, or sell securities on Upstream. There can be no assurance the valuation of any particular company's securities is accurate or in agreement with the market or industry comparative valuations. Investors must be able to afford market volatility and afford the loss of their investment. Companies listed on Upstream are subject to significant ongoing corporate obligations including, but not limited to disclosure, filings, and notification requirements, as well as compliance with applicable quantitative and qualitative listing standards.

Forward-Looking Information

This communication contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) difficulties in obtaining financing on commercially reasonable terms; (ii) changes in the size and nature of our competition; (iii) loss of one or more key executives or brand ambassadors; and (iv) changes in legal or regulatory requirements in the markets in which we operate. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contacts:

Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: [email protected]
Telephone: (833) 571-1811

Investor Relations
Email: [email protected], [email protected]
Website: www.quantumbiopharma.com

SOURCE: Quantum Biopharma Ltd.

S.Palmer--TFWP